Hypothesis

Persistent accumulation of non‑enzymatic AGEs in collagen creates a stiff extracellular matrix that engages integrin‑αvβ3‑FAK signaling, which in turn upregulates CD38 NADase activity in fibroblasts and macrophages. This coupling converts mechanical stress into a NAD+‑consuming signal that lowers cellular NAD+, suppresses sirtuin‑driven anabolic programs, and limits futile attempts to remodel a protease‑resistant matrix. When the mechanosensitive NAD+ brake is overridden, cells expend ATP on ineffective remodeling, exacerbating inflammation without functional gain.

Mechanistic basis

1. AGE‑modified collagen resists MMP degradation ([1][2]), raising tissue stiffness that is sensed by integrin‑αvβ3 focal adhesions.
2. Integrin ligation activates FAK autophosphorylation (Y397), leading to downstream ERK and NF‑κB pathways that have been shown to drive CD38 expression in senescent macrophages ([5]).
3. Elevated CD38 hydrolyzes NAD+ to ADP‑ribose, decreasing NAD+ availability for SIRT1/3 activity, which normally promotes FOXO‑mediated antioxidant genes and PGC‑1α‑driven mitochondrial biogenesis.
4. Low NAD+ shifts the cellular economy toward catabolism and away from energy‑intensive processes such as collagen synthesis and MMP secretion, effectively putting repair on hold until the matrix becomes degradable again.
5. This creates a feedback loop: stiff AGE‑rich matrix → integrin‑FAK‑CD38 ↑ → NAD+ ↓ → reduced anabolic/reparatory output → less new collagen deposition → slower accumulation of fresh substrate for glycation.

Testable predictions

• Prediction 1: In aged mouse tendon, pharmacological inhibition of FAK (e.g., PF‑573228) or genetic knockdown of integrin‑αvβ3 will reduce CD38 expression and restore NAD+ levels in resident fibroblasts, without altering AGE content.
• Prediction 2: Conversely, overexpressing a constitutively active FAK in young fibroblasts will increase CD38 activity, lower NAD+, and decrease collagen synthesis rates even when cultured on pliable, non‑glycated matrices.
• Prediction 3: If NAD+ is boosted (e.g., with NR) in aged mice that also receive an integrin‑β3 blocking antibody, the expected increase in SIRT1 activity will not translate into higher collagen turnover or improved tensile strength, indicating that the mechanical block persists.
• Prediction 4: Measuring focal adhesion kinase phosphorylation and CD38 mRNA in human biopsies of sarcopenic muscle should reveal a positive correlation with pentosidine‑collagen levels and an inverse correlation with NAD+ concentrations ([3][4]).

Falsifiability

If FAK or integrin blockade fails to modulate CD38/NAD+ in aged tissue, or if NAD+ supplementation improves functional outcomes despite persistent AGE cross‑linking, the hypothesis that the integrin‑FAK‑CD38 axis mediates a mechanosensitive NAD+ brake would be refuted.

Broader implication

This framework reframes NAD+ decline not as a passive metabolic wear‑and‑tear but as an active, mechanotransduced signal that halts energetically costly repair when the substrate is irreversibly damaged. Therapeutic strategies that ignore the mechanical context may drive maladaptive, ATP‑wasting remodeling, whereas combining NAD+ precursors with agents that modulate integrin‑FAK signaling could synchronize metabolic readiness with matrix degradability.